ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

OLGC Orthologic (MM)

0.865
0.00 (0.00%)
After Hours
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Orthologic (MM) NASDAQ:OLGC NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.865 0 01:00:00

OrthoLogic to Host Conference Call Discussing First Quarter 2006 Results

27/04/2006 3:00pm

PR Newswire (US)


Orthologic (MM) (NASDAQ:OLGC)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Orthologic  (MM) Charts.
TEMPE, Ariz., April 27 /PRNewswire-FirstCall/ -- OrthoLogic Corp. (NASDAQ:OLGC) announced today that it will release financial and operating results for 1Q2006 on Thursday, May 4, 2006. Management will host a conference call and Webcast the same day at 9:00AM EDT (6:00AM MT). The call may be accessed at 866-825-1692 (domestic) or 617- 213-8059 (international), with access code 66209515, or by logging onto the Investors section of the Company's Web site, http://www.orthologic.com/ . A replay will be available beginning May 4, 2006, at 11:00 AM EDT until May, 18, 2006, and may be accessed at 888-286-8010 (domestic) or 617-801-6888 (international), with access code 19681555. About OrthoLogic OrthoLogic is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under- served conditions. The Company is focused on the development and commercialization of two product platforms: Chrysalin(R) (TP508) and AZX100. Chrysalin, the Company's novel synthetic 23-amino acid peptide, is being studied in two lead indications, both of which represent areas of significant unmet medical need -- fracture repair and diabetic foot ulcer healing. Based on the Company's pioneering scientific research of the natural healing cascade, OrthoLogic has become a leading company focused on tissue and bone repair. The Company owns exclusive worldwide rights to Chrysalin. AZX100 is a novel synthetic 24-amino acid peptide, the first of a new class of compounds in the field of smooth muscle relaxation called Intracellular Actin Relaxing Molecules, or ICARMs(TM). AZX100 is currently being evaluated for medically and commercially significant applications, such as the treatment of vasospasm associated with subarachnoid hemorrhage, the prevention of keloid scarring and the treatment of asthma. OrthoLogic has an exclusive worldwide license to AZX100. DATASOURCE: OrthoLogic CONTACT: Investors, Melanie Friedman for OrthoLogic, +1-212-362-1200 or Web site: http://www.orthologic.com/

Copyright

1 Year Orthologic (MM) Chart

1 Year Orthologic  (MM) Chart

1 Month Orthologic (MM) Chart

1 Month Orthologic  (MM) Chart